immunogen


Also found in: Dictionary, Thesaurus, Medical, Legal, Wikipedia.
Related to immunogen: hapten, Tolerogen

immunogen

[ə′myü·nə·jən]
(immunology)
A substance which stimulates production of specific antibody or of cellular immunity, and which can react with these products.
Mentioned in ?
References in periodicals archive ?
Under terms of the agreement between ImmunoGen and SB, in addition to royalties, ImmunoGen could receive up-front cash and milestone payments totaling more than $40 million.
ImmunoGen, Inc. Receives Second Milestone Payment from SmithKline Beecham as Part of Colorectal Cancer Treatment Agreement
Blattler, 45, had been Vice President, Research, at ImmunoGen since 1987, when the Company moved its research out of Dana-Farber Cancer Institute and established its own laboratories.
IMMUNOGEN, INC., PROMOTES TWO IN RESEARCH AND DEVELOPMENT AND ANNOUNCES THE RESIGNATION OF ITS VICE PRESIDENT, CORPORATE DEVELOPMENT
CONTACT: Mark Ratner, director, external communications, of ImmunoGen, 617-661-9312/
IMMUNOGEN ANNOUNCES RESIGNATION OF PRESIDENT DONALD J. McCARREN
Small-drug immunoconjugates using humanized antibodies will be used as tumor debulking agents," adds ImmunoGen CEO Sayare "and therefore will complement our Oncolysin products, which are designed to prevent relapses once a patient is in remission.
IMMUNOGEN PUBLISHES RESULTS USING NOVEL ANTIBODY HUMANIZATION TECHNIQUE IN THE PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES
Over all, ImmunoGen has four Oncolysin conjugates in clinical trials in the treatment of various types of cancer.
IMMUNOGEN RECEIVES U.S. PATENT ON ITS CYTOTOXIC AGENT, BLOCKED RICIN, AND ITS USE IN CANCER THERAPEUTICS
Roussel-Uclaf had been working with ImmunoGen since 1989," states Mitchel Sayare, ImmunoGen chairman and chief executive officer.
IMMUNOGEN, INC. REGAINS EUROPEAN RIGHTS TO ONCOLYSIN B FROM ROUSSEL-UCLAF
Oncolysin CD6 is the fourth product ImmunoGen has brought into the clinic successfully," states Mitchel Sayare, chairman and chief executive officer.
ONCOLYSIN(R) CD6, IMMUNOGEN'S FOURTH PRODUCT, ENTERS PHASE I HUMAN CLINICAL TRIALS
May 17 /PRNewswire/ -- Clinical investigators have seen evidence of efficacy in the recently completed Phase I clinical trial of ImmunoGen, Inc.
DATA FROM IMMUNOGEN'S PHASE I CLINICAL TRIAL OF ONCOLYSIN S PRESENTED AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
ImmunoGen expects enrollment to be completed in one year and to be in position to prepare a Product License Application six to 18 months after that, in 1995.
IMMUNOGEN BEGINS PHASE III CLINICAL TRIAL OF ONCOLYSIN B
Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Bayer HealthCare Pharmaceuticals' submission of an Investigational New Drug (IND) application for the TAP compound, BAY 94-9343, triggers a $2 million milestone payment to ImmunoGen.
ImmunoGen, Inc. Earns Milestone with BAY 94-9343 IND Submission
Using the information obtained in this study, ImmunoGen will begin a dose-ranging Phase I/II clinical trial in patients who are in remission following conventional chemotherapy, to extend their period of disease- free survival.
IMMUNOGEN COMPLETES PHASE I TRIAL OF ONCOLYSIN S

Encyclopedia browser ?
Full browser ?